Open-label study with Nalmefene as needed use in alcohol-dependent patients with evidence of elevated liver stiffness and/or hepatic steatosis
AIMS: This open-label study in patients with alcohol dependence and evidence of elevated liver stiffness and/or hepatic steatosis was designed to explore the efficacy of nalmefene (18 mg) in reducing alcohol consumption and its subsequent effects on a variety of clinically relevant liver parameters....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
12 November 2019
|
| In: |
Alcohol and alcoholism
Year: 2020, Volume: 55, Issue: 1, Pages: 63-70 |
| ISSN: | 1464-3502 |
| DOI: | 10.1093/alcalc/agz078 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1093/alcalc/agz078 Verlag, Volltext: https://academic.oup.com/alcalc/article-abstract/55/1/63/5622719 
|
| Author Notes: | Sebastian Mueller, Mathias Luderer, Doris Zhang, Didier Meulien, Björn Steiniger Brach, Maiken Brix Schou |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1747722340 | ||
| 003 | DE-627 | ||
| 005 | 20240411193354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210208r20202020xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/alcalc/agz078 |2 doi | |
| 035 | |a (DE-627)1747722340 | ||
| 035 | |a (DE-599)KXP1747722340 | ||
| 035 | |a (OCoLC)1341391884 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mueller, Sebastian |e VerfasserIn |0 (DE-588)115640746X |0 (DE-627)1019235071 |0 (DE-576)502163038 |4 aut | |
| 245 | 1 | 0 | |a Open-label study with Nalmefene as needed use in alcohol-dependent patients with evidence of elevated liver stiffness and/or hepatic steatosis |c Sebastian Mueller, Mathias Luderer, Doris Zhang, Didier Meulien, Björn Steiniger Brach, Maiken Brix Schou |
| 264 | 1 | |c 12 November 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.02.2021 | ||
| 520 | |a AIMS: This open-label study in patients with alcohol dependence and evidence of elevated liver stiffness and/or hepatic steatosis was designed to explore the efficacy of nalmefene (18 mg) in reducing alcohol consumption and its subsequent effects on a variety of clinically relevant liver parameters. METHODS: Adult patients with a diagnosis of alcohol dependence and evidence of elevated liver stiffness and/or hepatic steatosis (liver stiffness >6 kPa or controlled attenuation parameter (CAP) >215 dB/m as measured by transient elastography) were recruited at two study sites in Germany. During the 12-week treatment period, patients were instructed to take nalmefene each day they perceived a risk of drinking alcohol. RESULTS: All 45 enrolled patients took at least one dose of nalmefene and 39 completed the study. After 12 weeks of study treatment with nalmefene patients showed a reduction in alcohol consumption of -13.5 days/month heavy drinking days and -45.8 g/day total alcohol consumption. Most liver parameters showed modest changes at Week 12; there was a 13% decrease in liver stiffness and 10% reduction in CAP values. Results indicated non-significant negative associations between alcohol consumption and liver stiffness and/or CAP over this 12-week study. Nalmefene was generally well tolerated, and most adverse events were mild or moderate, the most frequent being dizziness. CONCLUSIONS: Patients treated with nalmefene for 12 weeks had reductions in alcohol consumption by ~50% relative to baseline and showed trends to improvement in liver stiffness and CAP. | ||
| 534 | |c 2020 | ||
| 650 | 4 | |a Alcohol Drinking | |
| 650 | 4 | |a Alcoholism | |
| 650 | 4 | |a Elasticity | |
| 650 | 4 | |a Elasticity Imaging Techniques | |
| 650 | 4 | |a Fatty Liver | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Naltrexone | |
| 650 | 4 | |a Narcotic Antagonists | |
| 650 | 4 | |a Treatment Outcome | |
| 700 | 1 | |a Luderer, Mathias |d 1980- |e VerfasserIn |0 (DE-588)1060475960 |0 (DE-627)800001974 |0 (DE-576)416559859 |4 aut | |
| 700 | 1 | |a Zhang, Doris |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meulien, Didier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brach, Björn Steiniger |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schou, Maiken Brix |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alcohol and alcoholism |d Oxford : Oxford Univ. Press, 1963 |g 55(2020), 1, Seite 63-70 |h Online-Ressource |w (DE-627)300897014 |w (DE-600)1483492-3 |w (DE-576)096290439 |x 1464-3502 |7 nnas |a Open-label study with Nalmefene as needed use in alcohol-dependent patients with evidence of elevated liver stiffness and/or hepatic steatosis |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:1 |g pages:63-70 |g extent:8 |a Open-label study with Nalmefene as needed use in alcohol-dependent patients with evidence of elevated liver stiffness and/or hepatic steatosis |
| 856 | 4 | 0 | |u https://doi.org/10.1093/alcalc/agz078 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/alcalc/article-abstract/55/1/63/5622719 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210208 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 115640746X |a Mueller, Sebastian |m 115640746X:Mueller, Sebastian |d 50000 |e 50000PM115640746X |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1747722340 |e 3849748529 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"12 November 2019","dateIssuedKey":"2020"}],"note":["Gesehen am 08.02.2021"],"recId":"1747722340","name":{"displayForm":["Sebastian Mueller, Mathias Luderer, Doris Zhang, Didier Meulien, Björn Steiniger Brach, Maiken Brix Schou"]},"title":[{"title":"Open-label study with Nalmefene as needed use in alcohol-dependent patients with evidence of elevated liver stiffness and/or hepatic steatosis","title_sort":"Open-label study with Nalmefene as needed use in alcohol-dependent patients with evidence of elevated liver stiffness and/or hepatic steatosis"}],"relHost":[{"language":["eng"],"part":{"issue":"1","pages":"63-70","text":"55(2020), 1, Seite 63-70","volume":"55","extent":"8","year":"2020"},"pubHistory":["[1.]1963; 2.1965/67 -"],"title":[{"title_sort":"Alcohol and alcoholism","subtitle":"the international journal of the Medical Council on Alcoholism (MCA) and the journal of the European Society for Biomedical Research on Alcoholism (ESBRA)","title":"Alcohol and alcoholism"}],"id":{"eki":["300897014"],"zdb":["1483492-3"],"issn":["1464-3502"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Open-label study with Nalmefene as needed use in alcohol-dependent patients with evidence of elevated liver stiffness and/or hepatic steatosisAlcohol and alcoholism","recId":"300897014","titleAlt":[{"title":"Bulletin on alcoholism"},{"title":"The journal of alcoholism"},{"title":"British journal on alcohol and alcoholism"}],"corporate":[{"role":"isb","display":"Medical Council on Alcoholism"},{"role":"isb","display":"European Society for Biomedical Research on Alcoholism"}],"origin":[{"dateIssuedDisp":"1963-","publisher":"Oxford Univ. Press","publisherPlace":"Oxford","dateIssuedKey":"1963"}]}],"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1093/alcalc/agz078"],"eki":["1747722340"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"person":[{"role":"aut","display":"Mueller, Sebastian","given":"Sebastian","family":"Mueller"},{"role":"aut","display":"Luderer, Mathias","given":"Mathias","family":"Luderer"},{"role":"aut","display":"Zhang, Doris","given":"Doris","family":"Zhang"},{"family":"Meulien","given":"Didier","display":"Meulien, Didier","role":"aut"},{"role":"aut","display":"Brach, Björn Steiniger","given":"Björn Steiniger","family":"Brach"},{"given":"Maiken Brix","family":"Schou","role":"aut","display":"Schou, Maiken Brix"}]} | ||
| SRT | |a MUELLERSEBOPENLABELS1220 | ||